STOCKHOLM, May 7, 2019 /PRNewswire/ -- Medivir
AB (Nasdaq Stockholm: MVIR) today announces that data from
the investigator-initiated study evaluating the effects of
remetinostat in basal cell carcinoma patients, will be presented
during the 2019 Society for Investigative Dermatology (SID) annual
meeting in Chicago, USA.
Data will be presented on a poster and orally on May 10 and 11, respectively. The title of the
abstract is: "An Open-Label Phase 2 Clinical Trial of Topical
Remetinostat Gel for Basal Cell Carcinoma".
Authors: Nicole Urman
B.S., Shaundra Eichstadt
M.D., Hanh Do B.S., Amar Mirza
B.S., Irene Bailey Ph.D., Shufeng Li Ph.D., Stanley T. Hollmig, Jean
Y. Tang M.D. Ph.D., Anthony E. Oro
M.D. Ph.D., Sumaira Aasi
M.D., and Kavita Y. Sarin
M.D. Ph.D.
Details of all presentations for the 2019 SID annual meeting are
available at the conference
website:https://www.sidannualmeeting.org/
For further information, please contact:
Uli Hacksell,
CEO, Medivir AB, phone: +46(0)73-125-0615
About Medivir
Medivir develops innovative drugs with a focus on cancer where
the unmet medical needs are high. The company is investing in
indication areas where available therapies are limited or missing
and there are great opportunities to offer significant improvements
to patients. Collaborations and partnerships are important parts of
Medivir's business model and the drug development as well as the
commercialization is conducted either by Medivir or in partnership.
Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's
Small Cap list. www.medivir.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/medivir/r/data-from-the-remetinostat-phase-ii-study-in-basal-cell-carcinoma-patients-to-be-presented-at-the-20,c2805210
The following files are available for download:
|
https://mb.cision.com/Main/652/2805210/1038636.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/data-from-the-remetinostat-phase-ii-study-in-basal-cell-carcinoma-patients-to-be-presented-at-the-2019-sid-annual-meeting-300844932.html
SOURCE Medivir
